CKConstantinos Kallis

Constantinos Kallis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Constantinos Kallis has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Predicting asthma adverse events in UK adults who do not engage with asthma care

    by Constantinos Kallis, Amy Trinh, David Lo, Erol Gaillard, Hilary Pinnock, Jenni Quint

    Background: The UK ranks amongst the highest asthma mortality rates in Europe with over one-third of deaths potentially preventable with better routine care. We built and compared prediction methods for the outcome variable defined as asthma adverse events (poor control of asthma or having ≥ 1 asthma attack) in adults who did not engage with routine asthma care 12-24 months post-diagnosis. Methods: Using CPRD primary care AURUM data linked with hospital and mortality data from 2010-2020, we included 1,206,547 adults with asthma to estimate the association of candidate predictors using Odds Ratios (ORs) with the outcome variable (n=137,625, 11%) with logistic regression. We also estimated the predictive accuracy using Area Under ROC curve (AUC), calibration and decision curve analysis from a variety of prediction methods. Results: Non-engagement with asthma care services, poor control of asthma and ≥ 1 asthma attack in last 12 months were significantly associated with non-engagement and poor control/attacks in the subsequent 12-months adjusted for demographic and clinical characteristics (Fig.1). Gradient boosting, a machine learning method based on a combination of sequentially better models, achieved the best discrimination (AUC = 0.71). Calibration curves helped identify gradient boosting as the best model. Competing models had slightly lower accuracy. Conclusions: Gradient boosting was the best model. Further research to improve predictive accuracy is required for use within routine clinical practice. erj;68/suppl_70/PA5946/F1 F1 F1

  • Open Access

    One Year Risk Prediction Model for Cardiovascular Disease for Adults with Asthma in England

    by Jessica Baskaran, Vesselin Novov, Jennifer Quint, Constantinos Kallis

    Background: Cardiovascular disease (CVD) continues to be a significant health threat to humans globally, and a significant burden on healthcare systems. Cardiovascular risk prediction utilizing machine learning (ML) models in patients with asthma remains vastly underexplored. Methods: In this cohort study consisting of 641,042 participants, we used routinely collected electronic healthcare record data to explore various ML algorithms including logistic regression, penalized logistic regression, decision trees, random forest and gradient boost to develop a model with high specificity. Results: The penalized logistic regression model was identified to be the best and simplest classification model in terms of discriminatory power (AUC = 0.85). The gradient boost model was found to be the best predictive model in terms of calibration where the predicted and observed probabilities at risk of CVD match or are closely aligned. In all models, the number of previous cardiovascular events was the most influential predictor, followed by age and prescriptions related to cardiovascular medications. The top predictor alone produced a reasonable level of predictive power (AUC = 0.66). Conclusion: We have created a novel prediction model for predicting CVD within a year of asthma diagnosis for patients with asthma at least 50 years old. Using penalized logistic regression, we achieved a high level of accuracy. By implementing this model, it would be possible to screen out patients with low risk of CVD with high specificity and acceptable sensitivity. Penalized logistic regression and gradient boost models have similar accuracy in screening out individuals at low risk of CVD. For this objective, penalized logistic regression may be more suitable than gradient boost models for implementation as it is simpler to use and more transparent. At the probability threshold of 8% (outcome prevalence), both models’ effectiveness in reducing unnecessary treatments was by approximately 52%. These ML models performed better compared with traditional statistical-based risk prediction models. The unique contribution of the study is the construction of prediction models for CVD disease within 12 months from asthma diagnosis based on regression and machine learning models and the comparison of their accuracy to identify the best model based on suitable statistical measures such as AUC and calibration. Further prospective studies using different populations and external validation are required to assess and validate the ML risk prediction models.


  • Open Access

    Mapping Use of High Dose or Long‐Term Oral Glucocorticoids and Steroid‐Sparing Strategies in Adults With Chronic Conditions: A Rapid Scoping Review of Reviews

    by Elizabeth Moore, Mohammad Al Sallakh, Olufemi Olajide, Daira Trusinska, Tracy Jackson, Ting Shi, Sara J. Brown, Joanna C. Robson, Mwidimi Ndosi, Meghna Jani, et al.

    Purpose: Oral glucocorticoids (OGCs) have a broad range of uses and are effective in treating numerous conditions. However, it is commonly acknowledged that OGCs at high doses or over long periods have a burden of toxicity. Despite the use of steroid‐sparing therapies, OGCs continue to be prescribed to treat a wide range of immune and inflammatory conditions. We aimed to address the following research questions: (1) what are the contemporary indications for high dose and/or long‐term OGCs? (2) what patterns of use are described in the literature for high dose and/or long‐term OGCs? (3) which evidence do we have for chronic conditions related to well‐established steroid‐sparing strategies and tapering regimes for OGCs? (4) what adverse effects have been reported with high dose and/or long‐term OGCs? Methods: A rapid scoping review was conducted using the Joanna Briggs Institute guidelines. The Protocol has been published on the Open Science Framework. A systematic search of MEDLINE (Sep 2014 to Sep 2024) identified systematic reviews and scoping reviews involving adults (≥ 18 years) treated with high doses and/or long‐term OGCs for chronic inflammatory conditions. Studies involving pregnant women were excluded. Results: In total, 137 reviews were included. OGCs were indicated in 47 different conditions in dermatology, respiratory, gastrointestinal, hematology, immunology, rheumatology, and other miscellaneous categories. Across all specialties, OGCs were used either at high doses (at least 20 mg prednisone equivalent per day) or for long durations (for at least 3 months). For types of adverse effects reported in the included reviews, 20 were labeled as endocrine, 13 as immunological, 21 as musculoskeletal, 30 as gastrointestinal, and 16 as cardiovascular. Sixty‐four reviews looked for/reported unspecified adverse events. One hundred and fifteen reviews had evidence of steroid‐sparing/tapering regimes, indicating the wide use of these strategies to mitigate the harmful effects of OGCs. Conclusion: OGCs are used for a broad range of inflammatory conditions across multiple specialties. There is evidence related to a broad range of potential adverse effects across multiple body systems regardless of the indication of use. Further research is needed using a combined cross‐condition approach to their measurement and reduction, alongside gaining more insight into the impact of OGCs on patients' quality of life.


  • Open Access

    A Systematic Review of Codelists to Identify Chronic Bronchitis and Emphysema in Routine Electronic Healthcare Record Data and Derivation of a Standardized Codelist for Future Research

    by Harley Kwok, Georgie Massen, Alexander Adamson, Constantinos Kallis, Adam Lahmami, Yaqoob Sheikh, Mohammed Elseddig, Nabaz Mutabchi, Jennifer Quint

    Medical codes and codelists are essential to identify diseases, medicines, and related events when using electronic healthcare records (EHRs) for research. As multiple codes can be used to define the same medical condition, an inconsistency of applying codes by clinicians or researchers may complicate the identification of diseases. To minimize the inconsistency of codes and increase the comparability of research findings, we sought to integrate all medical codes and codelists generated from existing studies to produce a single list of codes for both chronic bronchitis and emphysema for future research. We systematically reviewed studies, which included codes used to define chronic bronchitis and/or emphysema regardless of code systems. We searched MEDLINE, Embase, Web of Science, Scopus, CINAHL, and Global Health from 1st January 2000 to May 2024 for relevant studies. Medical codes or codelists were identified, extracted, and compiled into single codelists for chronic bronchitis and emphysema separately based on their frequency of appearance across all included studies (PROSPERO: CRD42024529169). We identified 18 studies containing codelists, from a total of 1082 studies. Only International Classification of Disease (ICD) codes were found in studies, which defined chronic bronchitis and emphysema. Chronic bronchitis was defined as 490 and 491 in ICD-9 and J40, J41, J42, and J44 in ICD-10. Meanwhile, emphysema was defined as 492 in ICD-9 and J43 in ICD-10. Additionally, to fill the current gap, we created SNOMED CT codelists for both chronic bronchitis and emphysema, to standardize the definitions of these diseases in future studies.


  • Open Access

    Incidence and prevalence of asthma, chronic obstructive pulmonary disease and interstitial lung disease between 2004 and 2023: harmonised analyses of longitudinal cohorts across England, Wales, South-East Scotland and Northern Ireland

    by Hannah Whittaker, Adriana Kramer Fiala Machado, Sara Hatam, Sarah Cook, Sean Scully, Hywel Turner T Evans, Thomas Bolton, Constantinos Kallis, John Busby, Liam G Heaney, et al.

    Background We describe the epidemiology of asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) from 2004 to 2023 in England, Wales, Scotland and Northern Ireland (NI) using a harmonised approach. Methods Data from the National Health Service England (NHSE), Clinical Practice Research Datalink Aurum in England, Secure Anonymised Information Linkage Databank in Wales, DataLoch in South-East Scotland and the Honest Broker Service in NI were used. A harmonised approach to COPD, asthma and ILD case definitions, study designs and study populations across the four nations was performed. Age-sex-standardised incidence rates and point prevalence were calculated between 2004 and 2023 depending on data availability. Logistic and negative binomial regression compared incidence and prevalence rates between the start and end of each study period. Linear extrapolation projected incidence rates between 2020 and 2023 to illustrate how observed and projected rates differed. Results Incidence rates were lower in 2019 versus 2005 for asthma (England: incidence rate ratio 0.89, 95% CI 0.88 to 0.90; Wales: 0.66, 0.65 to 0.68; Scotland: 0.67, 0.64 to 0.71; NI: 0.84, 0.81 to 0.86), COPD (England: 0.83, 0.82 to 0.85; Wales: 0.67, 0.65 to 0.69) and higher for ILD (England: 3.27, 3.05 to 3.50; Wales: 1.39, 1.27 to 1.53; Scotland: 1.63, 1.36 to 1.95; NI: 3.03, 2.47 to 3.72). In NHSE, the incidence of asthma was similar in June 2023 versus November 2019, but lower for COPD and higher for ILD. Prevalence of asthma in 2019 in England, Wales, Scotland and NI was 9.7%, 15.9%, 13.2% and 7.0%, respectively, for COPD 4.5%, 5.1%, 4.4% and 3.0%, and for ILD 0.4%, 0.5%, 0.6% and 0.3%. Projected incidence rates were 2.8, 3.4 and 1.8 times lower for asthma, COPD and ILD compared with observed rates at the height of the pandemic. Interpretation Asthma, COPD and ILD affect over 10 million people across the four nations, and a substantial number of diagnoses were missed during the pandemic.


  • Open Access

    Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease

    by Anne E Ioannides, Constantinos Kallis, Hannah R Whittaker, Jennifer K Quint

    Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship. Methods We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes. Measurements and main results Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), pConclusions ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.


  • Open Access

    Recent trends in asthma diagnosis, preschool wheeze diagnosis and asthma exacerbations in English children and adolescents: a SABINA Jr study

    by Constantinos Kallis, Ekaterina Maslova, Ann D Morgan, Ian Sinha, Graham Roberts, Ralf J P van der Valk, Jennifer K Quint, Trung N Tran

    Background: Asthma-related burden remains poorly characterised in children in the UK. We quantified recent trends in asthma prevalence and burden in a UK population-based cohort (1‒17-year-olds).Methods: The Clinical Practice Research Datalink Aurum database (2008‒2018) was used to assess annual asthma incidence and prevalence in 1‒17-year-olds and preschool wheeze in 1‒5-year-olds, stratified by sex and age. During the same period, annual asthma exacerbation rates were assessed in those with either a diagnosis of preschool wheeze or asthma.Results: Annual asthma incidence rates decreased by 51% from 1403.4 (95% CI 1383.7 to 1423.2) in 2008 to 688.0 (95% CI 676.3 to 699.9) per 105person-years (PYs) in 2018, with the most pronounced decrease observed in 1‒5-year olds (decreasing by 65%, from 2556.9 (95% CI 2509.8 to 2604.7) to 892.3 (95% CI 866.9 to 918.3) per 105PYs). The corresponding decreases for the 6‒11- and 12‒17-year-olds were 36% (1139.9 (95% CI 1110.6 to 1169.7) to 739.9 (95% CI 720.5 to 759.8)) and 20% (572.3 (95% CI 550.4 to 594.9) to 459.5 (95% CI 442.9 to 476.4)) per 105PYs, respectively. The incidence of preschool wheeze decreased over time and was slightly more pronounced in the 1‒3 year-olds than in the 4-year-olds. Prevalence of asthma and preschool wheeze also decreased over time, from 18.0% overall in 2008 to 10.2% in 2018 for asthma. Exacerbation rates increased over time from 1.33 (95% CI 1.31 to 1.35) per 10 PYs in 2008 to 1.81 (95% CI 1.78 to 1.83) per 10 PYs in 2018.Conclusion: Paediatric asthma incidence decreased in the UK since 2008, particularly in 1–5-year-olds; this was accompanied by a decline in asthma prevalence. Preschool wheeze incidence also decreased in this age group. However, exacerbation rates have been increasing.


  • Open Access

    Evaluation of data processing pipelines on real-world electronic health records data for the purpose of measuring patient similarity

    by Maria Pikoula, Constantinos Kallis, Sephora Madjiheurem, Jennifer K. Quint, Mona Bafadhel, Spiros Denaxas

    Background: The ever-growing size, breadth, and availability of patient data allows for a wide variety of clinical features to serve as inputs for phenotype discovery using cluster analysis. Data of mixed types in particular are not straightforward to combine into a single feature vector, and techniques used to address this can be biased towards certain data types in ways that are not immediately obvious or intended. In this context, the process of constructing clinically meaningful patient representations from complex datasets has not been systematically evaluated. Aims: Our aim was to a) outline and b) implement an analytical framework to evaluate distinct methods of constructing patient representations from routine electronic health record data for the purpose of measuring patient similarity. We applied the analysis on a patient cohort diagnosed with chronic obstructive pulmonary disease. Methods: Using data from the CALIBER data resource, we extracted clinically relevant features for a cohort of patients diagnosed with chronic obstructive pulmonary disease. We used four different data processing pipelines to construct lower dimensional patient representations from which we calculated patient similarity scores. We described the resulting representations, ranked the influence of each individual feature on patient similarity and evaluated the effect of different pipelines on clustering outcomes. Experts evaluated the resulting representations by rating the clinical relevance of similar patient suggestions with regard to a reference patient. Results: Each of the four pipelines resulted in similarity scores primarily driven by a unique set of features. It was demonstrated that data transformations according to each pipeline prior to clustering can result in a variation of clustering results of over 40%. The most appropriate pipeline was selected on the basis of feature ranking and clinical expertise. There was moderate agreement between clinicians as measured by Cohen’s kappa coefficient. Conclusions: Data transformation has downstream and unforeseen consequences in cluster analysis. Rather than viewing this process as a black box, we have shown ways to quantitatively and qualitatively evaluate and select the appropriate preprocessing pipeline.


  • Open Access

    Assessing the Feasibility of a Text-Based Conversational Agent for Asthma Support: Protocol for a Mixed Methods Observational Study

    by Rafael A Calvo, Dorian Peters, Laura Moradbakhti, Darren Cook, Georgios Rizos, Bjoern Schuller, Constantinos Kallis, Ernie Wong, Jennifer Quint

    Background: Despite efforts, the UK death rate from asthma is the highest in Europe, and 65% of people with asthma in the United Kingdom do not receive the professional care they are entitled to. Experts have recommended the use of digital innovations to help address the issues of poor outcomes and lack of care access. An automated SMS text messaging–based conversational agent (ie, chatbot) created to provide access to asthma support in a familiar format via a mobile phone has the potential to help people with asthma across demographics and at scale. Such a chatbot could help improve the accuracy of self-assessed risk, improve asthma self-management, increase access to professional care, and ultimately reduce asthma attacks and emergencies. Objective: The aims of this study are to determine the feasibility and usability of a text-based conversational agent that processes a patient’s text responses and short sample voice recordings to calculate an estimate of their risk for an asthma exacerbation and then offers follow-up information for lowering risk and improving asthma control; assess the levels of engagement for different groups of users, particularly those who do not access professional services and those with poor asthma control; and assess the extent to which users of the chatbot perceive it as helpful for improving their understanding and self-management of their condition. Methods: We will recruit 300 adults through four channels for broad reach: Facebook, YouGov, Asthma + Lung UK social media, and the website Healthily (a health self-management app). Participants will be screened, and those who meet inclusion criteria (adults diagnosed with asthma and who use WhatsApp) will be provided with a link to access the conversational agent through WhatsApp on their mobile phones. Participants will be sent scheduled and randomly timed messages to invite them to engage in dialogue about their asthma risk during the period of study. After a data collection period (28 days), participants will respond to questionnaire items related to the quality of the interaction. A pre- and postquestionnaire will measure asthma control before and after the intervention. Results: This study was funded in March 2021 and started in January 2022. We developed a prototype conversational agent, which was iteratively improved with feedback from people with asthma, asthma nurses, and specialist doctors. Fortnightly reviews of iterations by the clinical team began in September 2022 and are ongoing. This feasibility study will start recruitment in January 2023. The anticipated completion of the study is July 2023. A future randomized controlled trial will depend on the outcomes of this study and funding. Conclusions: This feasibility study will inform a follow-up pilot and larger randomized controlled trial to assess the impact of a conversational agent on asthma outcomes, self-management, behavior change, and access to care. International Registered Report Identifier (IRRID): PRR1-10.2196/42965